RIOK2

Serine/threonine-protein kinase RIO2 · Q9BVS4 · RIOK2 on Sugi Atlas →

10,759 patent compounds predicted against RIOK2, 7,831 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL928827	0.58	8/20
Maleic Acid (SCHEMBL994794)	0.53	8/20
Fumaric Acid (SCHEMBL994795)	0.53	8/20
Bgt-226 Free Base (SCHEMBL146939)	0.74	7/20
SCHEMBL627307	0.48	7/20
Bgt-226 Free Base (SCHEMBL996046)	0.67	6/20
Bgt-226 Free Base (SCHEMBL996047)	0.67	6/20
SCHEMBL560081	0.53	6/20
SCHEMBL928275	0.63	5/20
SCHEMBL927554	0.60	5/20
SCHEMBL927556	0.60	5/20
Maleic Acid (SCHEMBL996448)	0.55	5/20
Fumaric Acid (SCHEMBL996449)	0.55	5/20
Fumaric Acid (SCHEMBL996450)	0.55	5/20
SCHEMBL971878	0.48	5/20
SCHEMBL221201	0.62	4/20
SCHEMBL576627	0.62	4/20
SCHEMBL928292	0.62	4/20
SCHEMBL928009	0.60	4/20
SCHEMBL929491	0.58	4/20

Clinical trials — most relevant to RIOK2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas	PHASE1/PHASE2	COMPLETED
Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
KRAS Wild-type Metastatic Colorectal Cancer Trial	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated or Spliceosome Mutated Relapsed or Refractory Acute Myeloid Leukemia	PHASE1	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212	PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Biomarkers in Samples From Patients With Endometrial Cancer	nan	WITHDRAWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
Characterization of New Candidate Genes in Cases of Human Inherited Thrombocytopenia (CATCH)	nan	COMPLETED
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia	nan	RECRUITING
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
MicroRNA-1 (miRNA-1) and MicroRNA-133a (miRNA-133a) Levels After Acute Exercise in Ultimate Frisbee Athletes	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RIOK2 binder may also engage these)

Protein	Name	Similarity
Q9CQS5	—	1.000	Q9CQS5 →
P40160	—	0.992	P40160 →
Q92562	—	0.990	Q92562 →
Q9C813	—	0.990	Q9C813 →
Q95Q34	—	0.988	Q95Q34 →
Q7YZT6	—	0.988	Q7YZT6 →
A6QQR4	—	0.988	A6QQR4 →
Q5SVQ0	—	0.988	Q5SVQ0 →
Q92539	—	0.988	Q92539 →
A8QFQ3	—	0.988	A8QFQ3 →
Q580W5	—	0.988	Q580W5 →
A8WRG3	—	0.987	A8WRG3 →
Q60L58	—	0.987	Q60L58 →
P91351	—	0.987	P91351 →
O01991	—	0.987	O01991 →
F4JZ68	—	0.987	F4JZ68 →
A2A3K4	—	0.987	A2A3K4 →
O61608	—	0.987	O61608 →
Q19192	—	0.987	Q19192 →
Q4R8E0	—	0.987	Q4R8E0 →
Q08AX9	—	0.987	Q08AX9 →
A8E7C5	—	0.987	A8E7C5 →
KAT7	Histone acetyltransferase KAT7	0.987	landscape →
E1B7X9	—	0.987	E1B7X9 →
A8XQD5	—	0.987	A8XQD5 →
Q6P158	—	0.986	Q6P158 →
Q2LYK3	—	0.986	Q2LYK3 →
Q6E3D4	—	0.986	Q6E3D4 →
O97143	—	0.986	O97143 →
I2HAA0	—	0.986	I2HAA0 →